166 related articles for article (PubMed ID: 31100506)
21. Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST.
Hombach M; Somoskövi A; Hömke R; Ritter C; Böttger EC
Int J Med Microbiol; 2013 Jul; 303(5):270-6. PubMed ID: 23689069
[TBL] [Abstract][Full Text] [Related]
22. Molecular characterization of Mycobacterium kansasii isolates in the State of São Paulo between 1995-1998.
Chimara E; Giampaglia CM; Martins MC; Telles MA; Ueki SY; Ferrazoli L
Mem Inst Oswaldo Cruz; 2004 Nov; 99(7):739-43. PubMed ID: 15654431
[TBL] [Abstract][Full Text] [Related]
23. Treatment of pulmonary disease caused by Mycobacterium kansasii.
Huang HL; Lu PL; Lee CH; Chong IW
J Formos Med Assoc; 2020 Jun; 119 Suppl 1():S51-S57. PubMed ID: 32505588
[TBL] [Abstract][Full Text] [Related]
24. Clinical manifestations, antibiotic susceptibility and molecular analysis of Mycobacterium kansasii isolates from a university hospital in Taiwan.
Wu TS; Leu HS; Chiu CH; Lee MH; Chiang PC; Wu TL; Chia JH; Su LH; Kuo AJ; Lai HC
J Antimicrob Chemother; 2009 Sep; 64(3):511-4. PubMed ID: 19584102
[TBL] [Abstract][Full Text] [Related]
25. [Nontuberculous mycobacterial pulmonary disease - The new ATS/ERS/ESCMID/IDSA Guideline].
Wagner D; Lange C
Dtsch Med Wochenschr; 2020 Aug; 145(16):1145-1151. PubMed ID: 32791550
[TBL] [Abstract][Full Text] [Related]
26. Mycobacterium kansasii.
Johnston JC; Chiang L; Elwood K
Microbiol Spectr; 2017 Jan; 5(1):. PubMed ID: 28185617
[TBL] [Abstract][Full Text] [Related]
27. Drug resistance profiles and related gene mutations in slow-growing non-tuberculous mycobacteria isolated in regional tuberculosis reference laboratories of Iran: a three year cross-sectional study.
Akrami S; Dokht Khosravi A; Hashemzadeh M
Pathog Glob Health; 2023 Feb; 117(1):52-62. PubMed ID: 35261334
[TBL] [Abstract][Full Text] [Related]
28.
Kim DH; Jhun BW; Moon SM; Kim SY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182533
[TBL] [Abstract][Full Text] [Related]
29. HSP65-PRA identification of non-tuberculosis mycobacteria from 4892 samples suspicious for mycobacterial infections.
Saifi M; Jabbarzadeh E; Bahrmand AR; Karimi A; Pourazar S; Fateh A; Masoumi M; Vahidi E
Clin Microbiol Infect; 2013 Aug; 19(8):723-8. PubMed ID: 22963505
[TBL] [Abstract][Full Text] [Related]
30. Drug susceptibility testing of nontuberculous mycobacteria.
van Ingen J; Kuijper EJ
Future Microbiol; 2014; 9(9):1095-110. PubMed ID: 25340838
[TBL] [Abstract][Full Text] [Related]
31. [Drug sensitivity analysis of Mycobacterium chelonae and Mycobacterium abscessus and evaluation of Etest for susceptibility testing].
Gui J; Wang F; Hong CY; Li JL; Liang J
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Aug; 36(8):567-71. PubMed ID: 24252731
[TBL] [Abstract][Full Text] [Related]
32. Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease.
Srivastava S; Pasipanodya J; Sherman CM; Meek C; Leff R; Gumbo T
Antimicrob Agents Chemother; 2015 Apr; 59(4):2273-9. PubMed ID: 25645830
[TBL] [Abstract][Full Text] [Related]
33. Clofazimine for the Treatment of Mycobacterium kansasii.
Srivastava S; Gumbo T
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844047
[No Abstract] [Full Text] [Related]
34. [Detection of rpoB mutations in rifampicin-resistant Mycobacterium kansasii].
Yoshida S; Suzuki K; Tsuyuguchi K; Iwamoto T; Tomita M; Okada M; Sakatani M
Kekkaku; 2006 Jul; 81(7):475-9. PubMed ID: 16910599
[TBL] [Abstract][Full Text] [Related]
35. GenoType NTM-DR Performance Evaluation for Identification of Mycobacterium avium Complex and Mycobacterium abscessus and Determination of Clarithromycin and Amikacin Resistance.
Huh HJ; Kim SY; Shim HJ; Kim DH; Yoo IY; Kang OK; Ki CS; Shin SY; Jhun BW; Shin SJ; Daley CL; Koh WJ; Lee NY
J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167842
[TBL] [Abstract][Full Text] [Related]
36. Investigation of the population structure of Mycobacterium abscessus complex strains using 17-locus variable number tandem repeat typing and the further distinction of Mycobacterium massiliense hsp65 genotypes.
Yoshida S; Arikawa K; Tsuyuguchi K; Kurashima A; Harada T; Nagai H; Suzuki K; Iwamoto T; Hayashi S
J Med Microbiol; 2015 Mar; 64(Pt 3):254-261. PubMed ID: 25596119
[TBL] [Abstract][Full Text] [Related]
37. An unusual lung mass post stem cell transplantation.
Lyons J; Vandenberghe E; Fahy R; McDonnell C; Keane J; McLaughlin AM
Transpl Infect Dis; 2014 Aug; 16(4):672-5. PubMed ID: 24995624
[TBL] [Abstract][Full Text] [Related]
38. An overview of drugs for the treatment of Mycobacterium kansasii pulmonary disease.
Srivastava S; Pasipanodya JG; Heysell SK; Boorgula GD; Gumbo T; McShane PJ; Philley JV
J Glob Antimicrob Resist; 2022 Mar; 28():71-77. PubMed ID: 34933140
[TBL] [Abstract][Full Text] [Related]
39.
Luo J; Yu X; Jiang G; Fu Y; Huo F; Ma Y; Wang F; Shang Y; Liang Q; Xue Y; Huang H
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760127
[TBL] [Abstract][Full Text] [Related]
40. Pulmonary
Padmapriyadarsini C; Nair D; Gomathi NS; Velayudham B
Indian J Med Microbiol; 2016; 34(4):516-519. PubMed ID: 27934834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
